BPTH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States...

Stats
今日成交量	41 289.00
平均成交量	1.47M
市值	4.32M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $-4.54 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0800
ATR14	$0.0220 (0.79%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-02	Cleaver Heath	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Aubert Paul	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Sherwood Aline	Buy	10 000	Common Stock Option (right to buy)
2023-05-02	Morris Douglas P	Buy	13 000	Common Stock Option (right to buy)
2023-05-02	Nielsen Peter Henry	Buy	105 000	Common Stock Option (right to buy)

INSIDER POWER
100.00
Last 88 transactions
Buy: 10 429 808 \| Sell: 661 335

音量相关性

長: -0.09 (neutral)

短: -0.43 (neutral)

Signal:(58.676) Neutral

Bio Path Holdings Inc 相关性

10 最正相关
BDTX	0.897
PXLW	0.89
IMAB	0.88
SHYF	0.879
FULC	0.876
CPIX	0.874
RMRM	0.873
IVA	0.872
QMCO	0.871
DADA	0.87

10 最负相关
LEDS	-0.893
PPBT	-0.881
CINC	-0.87
ASUR	-0.86
SNCR	-0.857
SLGG	-0.851
TSLA	-0.835
MTEK	-0.834
RIBT	-0.827
XOG	-0.823

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Bio Path Holdings Inc 相关性 - 货币/商品

-0.12
( neutral )

-0.26
( neutral )

0.00
( neutral )

0.05
( neutral )

-0.27
( neutral )

Bio Path Holdings Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-178 000 (0.00 %)
EPS:	$-33.64

FY	2023
营收:	$0
毛利润:	$-178 000 (0.00 %)
EPS:	$-33.64

FY	2022
营收:	$0
毛利润:	$-178 000 (0.00 %)
EPS:	$-38.03

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.550

Financial Reports:

No articles found.

Bio Path Holdings Inc

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.